Please assess the completion status of the following clinical trial:

Trial Title: Therapy to Elevate CD4 Counts in HIV-1 Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. HIV-1 patients must have confirmed HIV-1 disease, diagnosed using the standard criteria and be on antiretroviral therapy. Patients with inherited alpha-1 proteinase inhibitor deficiency (PIzz) must not have previously received alpha-1 proteinase inhibitor therapy. Uninfected volunteers will be age and gender matched.~2. HIV-1 patients must have measurable disease, defined as HIV-1 infected patients on antiretroviral therapy with undetectable HIV RNA (\<500 HIV-1 RNA copies/ml) and CD4 counts more than 200 and less than 400 cells/uL.~3. Age at least 18 years and under 65 years.~4. HIV-1 patients must have active alpha-1 proteinase inhibitor below 11uM (normal is 18-53 uM).~5. HIV-1 patients must have one year history (prior to the study) with CD4 counts greater than 200 and less than 400 cells/uL.~6. Volunteers must have no evidence of malignancy.~Exclusion Criteria:~1. Recent illness that will prevent the patient from participating in required study activities.~2. Patients receiving other investigational agents.~3. Patients with known malignancies.~4. Patients with more than 500 HIV RNA copies/mL.~5. Patients with more than 400 CD4 cells/uL.~6. Uncontrolled illness including, but not limited to, ongoing or active infection, myeloid dysplastic syndrome, anemia, bone marrow failure, DiGeorge Syndrome, thymic disorders, or psychiatric illness/social situations that would limit compliance with study requirements.

- Gender: MALE
- Minimum Age: 30 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- alpha-1 proteinase inhibitor in HIV (Type: EXPERIMENTAL): HIV-1 infected individuals treated with Alpha-1 proteinase inhibitor

Based on this trial design, predict the completion outcome and termination type (if applicable).